Good news for chronic migraine by unknown
Chronic migraine, with or without
analgesic overuse, is a frequent con-
dition. Its prevalence almost reaches
3% in the general population [1]. In
addition, it is one of the most fre-
quent reasons for consultation in a
general neurological department and
accounts for around one-third of vis-
its to headache centres. In spite of
this relevant frequency, its treatment
has remained almost forgotten. In
fact, patients approaching a migraine
frequency close to that required for
chronic migraine diagnosis (15 or
more days per month) have been
automatically excluded from conven-
tional trials for migraine prevention.
Several reasons explain this unfair
exclusion. Difficulties in its concep-
tual definition since the appearance
of the previous IHS Classification,
which led to Silberstein and Lipton’s
transformed migraine criteria [2],
were the first of these reasons.
Second is the concept that most of
these patients in fact suffered from
headache secondary to analgesic
overuse and that their treatment
would just be withdrawal. Finally,
and related to the previous idea is the
perception that these patients were
very difficult to treat and refractory
to all preventatives. The paper by
Peres et al. [3] appearing in this issue
supports those of us who think that
chronic migraine patients may specif-
ically improve with preventatives,
especially on topiramate, even if they
continue overusing symptomatic
treatments.
Peres et al. [3] treated 64 chronic
migraine patients, both with and with-
out analgesic overuse, with topira-
mate (median dose 100 mg/day). A
reduction in frequency higher than
50% occurred in 66% of these
patients after 12 weeks and was not
different in overusers vs. those who
were not overusers. Their results
totally concur with those coming
from different parts of the world and
using similar courses of treatment not
only with topiramate [4–8] but also
with other neuromodulators, such as
valproate [8, 9] or gabapentin [10]. It
can be argued, of course, that the
methodology of these trials is far
from ideal as they are open studies,
with the exception of the gabapentin
trial, where the advantage for placebo
was small. Fortunately the first avail-
able placebo-controlled data on the
treatment of chronic migraine with
topiramate are in line with those com-
ing from its open trials. Silvestrini et
al. [11] were the first to show that
topiramate at low doses, 50 mg daily,
is an effective therapeutic approach to
reducing headache frequency in
patients with chronic migraine and
analgesic overuse. In the recent EHF
Congress held in Valencia, Diener et
al. [12] reported a significant, and
clinically relevant, reduction in
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migraine frequency with topiramate
vs. placebo in patients also suffering
from chronic migraine and analgesic
overuse. These results could be sum-
marised by saying that chronic
migraine is a treatable condition with
a preventative such as topiramate,
regardless of concomitant overuse. It
does not mean that symptomatic treat-
ment withdrawal is not important in
the management of these patients.
Rational use of acute treatment, try-
ing to limit use to under 2 days per
week and avoiding abortive medica-
tions with high incidence of rebound
– such as combination analgesics,
opioids and ergotics – continues to be
a milestone in the management of
such patients. From data generated
with topiramate and from the clinical
experience of many of us, however, I
would also recommend an early use
of preventatives in chronic migraine
patients, together with the current
withdrawal instructions. Some chron-
ic migraine patients with no response
to individual preventatives can also
respond to combinations such as a β-
blocker plus topiramate (Pascual and
Leira, in preparation).
The good news for chronic
migraine patients does not seem to
stop at topiramate or other neuro-
modulators. Phase II results have
shown some efficacy of botulinum
toxin A injections for the treatment
of this condition [13]. Finally,
Matharu et al. [14] have reported
eight chronic migraine patients with
marked response with implantation
of bilateral suboccipital stimulators.
This beneficial response was main-
tained for a follow-up of 1.5 years.
All these still preliminary results
should change our mind on treating
chronic migraine patients. Their
management is not, obviously, easy,
but several approaches are  now
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